Synlogic, Inc.
(NASDAQ : SYBX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
1.35%198.291.3%$525.42m
GILDGilead Sciences, Inc.
1.40%66.890.9%$355.47m
ALXNAlexion Pharmaceuticals, Inc.
0.83%106.552.0%$330.51m
ILMNIllumina, Inc.
0.80%307.633.5%$318.43m
BIIBBiogen Inc.
2.47%241.441.3%$313.62m
CELGCelgene Corporation
0.42%99.371.3%$295.81m
VRTXVertex Pharmaceuticals Incorporated
1.67%179.091.9%$177.67m
AAgilent Technologies, Inc.
0.70%78.621.6%$177.10m
REGNRegeneron Pharmaceuticals, Inc.
2.87%294.362.6%$171.15m
SRPTSarepta Therapeutics, Inc.
-1.77%83.8514.6%$142.67m
EXASExact Sciences Corporation
0.00%103.4024.1%$138.75m
ACADACADIA Pharmaceuticals Inc.
-1.68%40.9813.9%$123.34m
INCYIncyte Corporation
2.73%80.252.5%$87.52m
ALDRAlder Biopharmaceuticals, Inc.
0.30%18.7210.2%$76.65m
BMRNBioMarin Pharmaceutical Inc.
0.07%76.054.3%$75.67m

Company Profile

Synlogic, Inc. is a clinical-stage biopharmaceutical company, which engages in drug discovery and development of synthetic biotic medicines. It focuses on SYNB1020 and SYNB1618, which are orally administered and target hyperammonemia and phenylketonuria. It also works on SYNB1891, an intratumorally administered which treats cancer. The company was founded by Jim Collins and Tim Lu on August 28, 2017, and is headquartered in Cambridge, MA.